<DOC>
	<DOCNO>NCT02923466</DOCNO>
	<brief_summary>This Phase 1 study design determine maximum tolerate dose ( MTD ) toxicity intratumoral administration VSV-IFNÎ²-NIS patient refractory advanced/metastatic solid tumor .</brief_summary>
	<brief_title>Trial Intratumoral Administration Recombinant Vesicular Stomatitis Virus Patients With Refractory Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Stomatitis</mesh_term>
	<mesh_term>Vesicular Stomatitis</mesh_term>
	<criteria>Be &gt; 18 year age day sign informed consent . Have histologically confirm diagnosis advance and/or metastatic solid tumor relapse and/or refractory standard therapy , define progression least one prior line therapy relapsed/metastatic set exist option felt provide clinical benefit . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 1 . Adequate hematological , liver kidney function . Must willing implement contraception throughout study 120 day receive study drug . Has receive investigational agent , chemotherapy , immunotherapy , radiotherapy molecular target agent within 4 week start treatment . Has history bone marrow solid organ transplant . Is pregnant breastfeeding , expect conceive father child within project duration trial , start prescreening screen visit 120 day last dose trial treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>refractory solid tumor</keyword>
</DOC>